Phase 3 DESTINY-Lung04 Trial Shows First-Line Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in HER2-Mutant NSCLC

Phase 3 DESTINY-Lung04 showed trastuzumab deruxtecan (T-DXd) extended median progression-free survival to 14.3 months from 8.3 months for pembrolizumab plus chemotherapy in first-line HER2-mutant advanced NSCLC (HR 0.63; P<0.0001). T-DXd also raised objective response rates to 70.0% versus 44.5% and lengthened response duration to 13.4 versus 9.7 months, supporting a potential new first-line standard. Overall survival was not improved at the current analysis (29.3 vs 33.1 months; HR 1.15), while T-DXd had substantially higher ILD/pneumonitis incidence of 20.8% versus 2.3%.

Analysis

The commercial upside is real but unlikely to be transformative for AstraZeneca (AZN) or Daiichi Sankyo (4568.T) at the group level: HER2-mutant disease is a small molecular subset, and penetration depends on broad next-generation sequencing at diagnosis rather than physician enthusiasm alone. The more important read-through is strategic: a first-line targeted-therapy win strengthens the franchise's ability to displace chemo-immunotherapy earlier in the treatment algorithm, raising lifetime value per identified patient and reinforcing ENHERTU's platform premium versus other ADC portfolios.

The limiting variable is tolerability, not efficacy. A high pneumonitis/ILD burden could drive intensive monitoring, dose interruptions and conservative use in patients with baseline lung compromise; that matters disproportionately in NSCLC, where respiratory reserve is limited. The absence of a favorable mature survival signal also leaves regulators, payers and oncologists room to restrict use until longer follow-up clarifies whether earlier progression control converts into survival or merely changes sequencing.

Near term, AZN and 4568.T could rerate modestly on anticipated first-line label expansion over the next 6-12 months, but conference data alone should not justify chasing. Merck (MRK) has a theoretical first-line displacement risk, yet this molecular niche is too small to move consolidated KEYTRUDA economics; consensus may overstate the negative read-through. The more consequential 6-18 month catalyst is whether the safety-management profile supports broad real-world persistence and whether testing rates expand the identifiable population.

Key Decisions for Investors

• Maintain a neutral-to-modest overweight in AZN and 4568.T rather than chase an event-day move; add only on regulatory-filing visibility or a post-data pullback. Underwrite this as a franchise-valuation catalyst, not a near-term earnings step-change.
• Use a 6-12 month AZN call spread only if implied volatility remains below the level reached around prior ENHERTU label-expansion events; target a capped-risk position sized for regulatory approval upside. Exit if updated survival follow-up remains unfavorable or if regulators signal a survival requirement.
• Do not short MRK on this result. Any localized loss of chemo-immunotherapy share is immaterial to its consolidated revenue base; a short thesis would require evidence that HER2 testing and targeted substitution are spreading into materially larger NSCLC populations.
• Track discontinuation rates, grade 3+ pneumonitis, treatment-related deaths and regulatory label language as thesis falsifiers. A restrictive pulmonary-monitoring requirement or materially worse real-world persistence would cap first-line adoption despite strong tumor-control metrics.